Plain-English translation of NCT07437105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing a new drug called to see if it is safe and how your body handles it. This is an early-stage study conducted in healthy people (not patients with cystic fibrosis). The goal is to understand what doses are safe and how the medication moves through your body.
Before any new medication can be used to treat patients, it must first be tested for safety in healthy volunteers. This study is the important first step to make sure this medication is safe enough to study further in people who actually have the disease it may one day treat.
You likely qualify if…
You likely don't qualify if…
You will receive either the experimental medication or a placebo (inactive substance that looks identical). The study has two parts: one where you take a single dose, and another where you take multiple doses over time. You'll have regular visits where researchers will check your health, ask about side effects, and take blood samples to measure how your body is processing the medication.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment target
~128 participants
Started
February 2026
Primary completion
March 2027
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Medical Information
Vertex Pharmaceuticals Incorporated
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.